DUBLIN, October 21, 2021--(BUSINESS WIRE)--The "Global Pharmaceutical Isolator Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Open Isolator and Closed Isolator), Pressure (Positive Pressure and Negative Pressure), Configuration, Application, and End User; and Geography" report has been added to ResearchAndMarkets.com's offering.
The pharmaceutical isolator market was valued at 5,966.07 million in 2021 and is projected to reach US$ 10,560.30 million by 2028; it is expected to grow at a CAGR of 8.5 % from 2021 to 2028.
The growth of the pharmaceutical isolator market is attributed to factors such as an increase in investments by the pharmaceutical and biotechnology industry and a regulatory framework to support the adoption of pharmaceutical isolators. However, the market is likely to get impacted by the high cost involved in the operation and maintenance of pharmaceutical isolators.
A pharmaceutical isolator is a device that keeps a pharmaceutical process or activity isolated from the operator and the rest of the world. This might be for the aim of safeguarding a process or activity from microbiological and/or nonviable contamination caused by the operator and the surrounding environment by creating a classified clean or classified aseptic environment. This is referred to as product protection. Moreover, it can be used in protecting the operator and the surrounding environment from hazards arising from the process or activity. This is referred to as "operator protection" or "containment."
A pharmaceutical isolator offers a superior sterile environment than conventional clean rooms. Positive or negative pressures inside the chamber prevent contamination due to operator interference. It ensures long-lasting sterility in accordance with pharmaceutical regulations related to the manufacturing of sterile medical products. Moreover, most of the experts agree that regulatory agencies are no longer impeding progress when it comes to technologies such as pharmaceutical isolators. The guidelines set by the US Food and Drug Administration (US FDA) and the European Medicines Agency regarding isolators play an important role in the adoption of isolators in comparison to cleanrooms. FDA mentions isolators 55 times in its latest guideline of manufacturing in an aseptic environment.
A well-designed positive pressure isolator, supported by adequate procedures for its maintenance, monitoring, and controls, offers significant advantages over traditional aseptic processing, including fewer opportunities for microbial contamination during processing. Moreover, FDA acknowledges the removal of operators in the critical areas of pharmaceutical manufacturing, which is expected to propel the adoption of pharmaceutical isolators in the coming years. Trend analysis shows an increasing number of pharmaceutical facilities using isolator technology in the US. In 1998, only 84 facilities were equipped with aseptic filling in isolators. This number increased to 174 facilities in 2000, 201 in 2002, and 258 in 2004. The growth in the number of facilities offering aseptic processing is related to the growth in the production of high-potency drugs. Hence, a supportive regulatory framework will increase the adoption of pharmaceutical isolators and subsequently drive the market.
The COVID-19 pandemic has become the most significant challenge across the world. It has disturbed various trades and businesses across the world. However, the pandemic has brought several growth opportunities to the pharmaceutical and biopharmaceutical companies to strengthen their research and development for innovating vaccines against the novel coronavirus. The companies are performing clinical trials to curb the spread of the COVID-19 virus. Thus, increased clinical trials will lead to vital opportunities for the pharmaceutical isolator providers for biopharmaceutical companies.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Pharmaceutical isolator market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global Pharmaceutical isolator market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Increase in Investments by Pharmaceutical and Biotechnology Industry
Regulatory Framework to Support Adoption of Pharmaceutical Isolators
High Cost Involved in Operation and Maintenance of Pharmaceutical Isolators
Growing Pharmaceutical and Biotechnological Industries in Emerging Economies
Adoption of Automation in Pharmaceutical Isolator
Schematic Engineering Industries
Hosokawa Micron Group
Fedegari Autoclavi S.p.A.
Bioquell (Ecolab Solution)
For more information about this report visit https://www.researchandmarkets.com/r/dbe4yb
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005672/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900